Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00UFZ
|
|||
| Former ID |
DNCL001600
|
|||
| Drug Name |
AMG 745
|
|||
| Indication | Muscle atrophy [ICD-11: FB32.Y; ICD-9: 728.2] | Phase 2 | [1] | |
| Company |
Amgen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Growth/differentiation factor 8 (GDF-8) | Target Info | Antagonist | [2] |
| Panther Pathway | TGF-beta signaling pathway | |||
| WikiPathways | Hypertrophy Model | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00975104) AMG 745 in Subjects With Age-associated Muscle Loss. U.S. National Institutes of Health. | |||
| REF 2 | The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle. 2011 September; 2(3): 143-151. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.